Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01443390 · ClinicalTrials.gov registry record
An Ancillary Pilot Trial Using Whole Genome Sequencing In Patients With Advance Refractory Cancer
A clinical trial of Advanced Cancer, sponsored by Scottsdale Healthcare.
- Completed
- Registry status
- 11
- Enrollment target
- 1
- Study location
NCT01443390: Completed study of Advanced Cancer, sponsored by Scottsdale Healthcare.
NCT01443390 is a study of Advanced Cancer that has completed, run by Scottsdale Healthcare. The registered enrollment target is 11 participants, below the 246-participant average among 122 other Advanced Cancer trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01443390, a study of Advanced Cancer, has completed, sponsored by Scottsdale Healthcare.
- COMPLETED
- Registry status
- 11 participants
- Enrollment target
- 1
- Study location
Study Summary
When a patient with advanced cancer consults with a member of the Phase I drug development team, the investigators utilize all information possible to try to select a therapy for that patient which has the best chance of working for them. This information includes: 1. Past published information 2. Clinical experience and judgement 3. Immunohistochemistry for specific targets (e.g., ER) 4. Standard sequencing (e.g., for K-Ras) and other methods now available. The investigators have a new tool which warrants early exploration for what role it might eventually play in the process of selecting the best therapy for an individual patient. The basis of the current ancillary exploratory study is to gain initial experience with the operational aspects of this whole genome sequencing in this setting.
Conditions Studied
Study Locations (1)
Arizona
- Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare - Scottsdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2011-09 |
| Est. Completion | 2013-03 |
What the finished NCT01443390 record still lists
NCT01443390 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 11 participants, a relatively small participant target, below the 246-participant average among 122 other Advanced Cancer trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Advanced Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT01443390 reports a single indexed study location in Arizona.
Frequently Asked Questions
What is clinical trial NCT01443390 about?
NCT01443390 is a clinical study titled "An Ancillary Pilot Trial Using Whole Genome Sequencing In Patients With Advance Refractory Cancer". When a patient with advanced cancer consults with a member of the Phase I drug development team, the investigators utilize all information possible to try to select a therapy for that patient which has the best chance of working for them. This information includes: 1. Past published information 2. ...
What is the current status of trial NCT01443390?
This trial is currently completed. The enrollment target is 11 participants. The study started on 2011-09. Estimated completion is 2013-03.
What conditions does trial NCT01443390 study?
This clinical trial studies the following conditions: Advanced Cancer.
Who is sponsoring clinical trial NCT01443390?
This trial is sponsored by Scottsdale Healthcare, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01443390 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01443390's enrollment target sits among peer trials
11 118th of 122 higher than 5 of 122 other Advanced Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluating Disparities in Precision Oncology
RECRUITING
-
BOLSTER: Learning New Skills to Thrive
RECRUITING · NA
-
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
RECRUITING · Phase 2
-
Longitudinal Screening for Financial Hardship to Improve Outcomes in Patients With Advanced Cancer
RECRUITING · NA
-
Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss
RECRUITING · Phase 1
-
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03114462 · 11 participants · Phase 1
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
- NCT06039709 · 11 participants · Phase 1
Sonodynamic Therapy in Patients With Recurrent GBM
- NCT06425380 · 11 participants · NA
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
- NCT06472661 · 11 participants · Early Phase 1
FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia